So what exactly do you think Wayne is positioning for with the appointment of an M&A adviser?
I can't see how they could be looking to acquire anything (no funds), so are we basically seeing a big 'for sale' sign? Surely you'd get a much better price after a feasibility study is completed/approved by the FDA and not before?
I'm a bit confused, there are only really two or three major potential buyers, why out-source the sale process and initiate it so early? Unless by getting an M&A advisory firm to throw around numbers several multiples higher than the current share price
helps get some FOMO happening between now and option expiry? helping ensure a cash injection from options exercising?
Hold | Held
Ann: Key Partnerships, page-7
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
-0.300(1.64%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.29 | $18.30 | $17.65 | $181.7K | 10.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30 | $17.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.00 | 499 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |